bluebird bio Inc (LTS:0HOH)
$ 0.3637 0 (0%) Market Cap: 73.46 Mil Enterprise Value: 371.21 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

bluebird bio Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2019 / 05:05PM GMT
Release Date Price: $151.33
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang, I'm the Senior Care Biotech Analyst at Barclays. It is my great pleasure to introduce our next speaker, Jeff Walsh, Chief Financial and Strategy Officer from bluebird.

Jeffrey T. Walsh
bluebird bio, Inc. - Chief Strategy Officer

There's a mic live here. Okay, I got it. I'm going to do it sitting down because I got in very late last night, I am kind of tired after a day of one-on-one's here. So if you guys don't mind. By the way, I have a few slides and it's really to introduce you to where we are as a company right now. And it's a pretty exciting time for bluebird as we hopefully are on the cusp of becoming a commercial stage company. It doesn't mean we're not at development stage. It doesn't mean we're not at research stage. But it's the first entrée for bluebird into this world. So really excited to be here Gena, and I look forward to getting some of the questions, and I know you have as well and any that others have.

I will be making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot